No Matter The Market, Options Trading Could Earn You More
There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.
Download it for free here!

Jack Schuler Biography and Net Worth

Director of Biodesix

Jack Schuler has served as a Director of the Company since June 2008. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the board from 1995 until Ventana’s acquisition by Roche in 2008. Prior to joining Ventana, Mr. Schuler was President and Chief Operating Officer of Abbott Laboratories, a diversified health care company, which he joined in 1972 and where he held a number of management and marketing positions, also serving as a director from April 1985 to August 1989. Additionally, Mr. Schuler has served as a director of Abbott Laboratories (NYSE:ABT), Medtronic (Lead Director) (NYSE: MDT), Stericyle (Chairman) (NASDAQ: SRCL), Chiron Corporation, and Quidel Corporation  (NASDAQ: QDEL), and currently serves on the board of directors of Accelerate Diagnostics (NASDAQ: AXDX). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University Graduate School of Business Administration.

What is Jack W. Schuler's net worth?

The estimated net worth of Jack W. Schuler is at least $30.04 million as of May 30th, 2023. Mr. Schuler owns 20,575,061 shares of Biodesix stock worth more than $30,039,589 as of June 7th. This net worth estimate does not reflect any other investments that Mr. Schuler may own. Learn More about Jack W. Schuler's net worth.

How do I contact Jack W. Schuler?

The corporate mailing address for Mr. Schuler and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Jack W. Schuler's contact information.

Has Jack W. Schuler been buying or selling shares of Biodesix?

During the last quarter, Jack W. Schuler has bought $152,824.82 in shares of Biodesix stock. Most recently, on Tuesday, May 30th, Jack W. Schuler bought 11,849 shares of Biodesix stock. The stock was acquired at an average cost of $1.36 per share, with a total value of $16,114.64. Following the completion of the transaction, the director now directly owns 20,575,061 shares of the company's stock, valued at $27,982,082.96. Learn More on Jack W. Schuler's trading history.

Who are Biodesix's active insiders?

Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.

Are insiders buying or selling shares of Biodesix?

During the last twelve months, Biodesix insiders bought shares 9 times. They purchased a total of 2,340,378 shares worth more than $2,913,387.17. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 71,593 shares worth more than $131,533.15. The most recent insider tranaction occured on May, 30th when Director Jack W Schuler bought 11,849 shares worth more than $16,114.64. Insiders at Biodesix own 63.8% of the company. Learn More about insider trades at Biodesix.

Information on this page was last updated on 5/30/2023.

Jack W. Schuler Insider Trading History at Biodesix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/30/2023Buy11,849$1.36$16,114.6420,575,061View SEC Filing Icon  
5/25/2023Buy52,508$1.36$71,410.8820,563,212View SEC Filing Icon  
5/23/2023Buy56,782$1.15$65,299.3020,475,396View SEC Filing Icon  
1/31/2023Buy10,000$2.41$24,100.0020,389,189View SEC Filing Icon  
1/27/2023Buy50,000$2.51$125,500.0020,379,189View SEC Filing Icon  
12/14/2022Buy189,675$1.65$312,963.7520,309,189View SEC Filing Icon  
12/12/2022Buy100,000$1.48$148,000.0020,052,112View SEC Filing Icon  
11/19/2021Buy60,000$6.50$390,000.00View SEC Filing Icon  
11/17/2021Buy20,000$6.51$130,200.00View SEC Filing Icon  
8/19/2021Buy50,000$7.69$384,500.00View SEC Filing Icon  
8/17/2021Buy29,440$7.18$211,379.20View SEC Filing Icon  
8/13/2021Buy232,000$7.50$1,740,000.00View SEC Filing Icon  
See Full Table

Jack W. Schuler Buying and Selling Activity at Biodesix

This chart shows Jack W Schuler's buying and selling at Biodesix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biodesix Company Overview

Biodesix logo
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $1.46
Low: $1.43
High: $1.53

50 Day Range

MA: $1.59
Low: $1.12
High: $1.88

2 Week Range

Now: $1.46
Low: $0.96
High: $3.00


40,373 shs

Average Volume

92,102 shs

Market Capitalization

$114.55 million

P/E Ratio


Dividend Yield



No Matter The Market, Options Trading Could Earn You More
There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.
Download it for free here!